Business
Viveve(R) to Present at Ladenburg Thalmann 2016 Healthcare Conference
Viveve(R) to Present at Ladenburg Thalmann 2016 Healthcare Conference.
About this update from Viveve Medical, Inc.
[{"type":"text","content":"\nViveve(R) to Present at Ladenburg Thalmann 2016 Healthcare Conference\n\nViveve(R) to Present at Ladenburg Thalmann 2016 Healthcare Conference\n\nSUNNYVALE, CA--(Marketwired - September 20, 2016) - Viveve Medical, Inc. (\"Viveve\") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that Patricia Scheller, chief executive officer, will present at the 2016 Ladenburg Thalmann Healthcare Conference, on Tuesday, September 27th. Ms. Scheller will present an update on global development and commercialization of the Viveve System, the company's lead product for use in the treatment of vaginal laxity.Event: Ladenburg Thalmann 2016 Healthcare ConferenceDate: Tuesday, September 27, 2016Time: 9:00-9:25 AM ESTLocation: St. Germain - Track 3 - Sofitel New York Hotel, 45 W 44th St, NYMs. Scheller and Scott Durbin, Viveve's chief financial officer, will be meeting with members of the investment community during one-on-one meetings at the conference. The presentation will be available for download on the company's web site at (www.viveve.com).About ViveveViveve Medical, Inc. is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the internationally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in many countries throughout the world and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.Safe Harbor StatementAll statements in this press release that are not based on historical fact are \"forward-looking statements\" within the meaning of Section 2...